

## CURRICULUM VITAE

### Deepak Kilari MD

Associate Professor  
Department of Medicine  
Division of Hematology and Oncology - Medicine

#### OFFICE ADDRESS:

Clinical Cancer Center  
9200 W Wisconsin Ave  
Milwaukee, WI 53226

#### EDUCATION:

09/1999 - 05/2005 M.B.B.S., Andhra Medical College, Visakhapatnam, India

#### INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

##### National

Novel therapeutic targets in Prostate Cancer, Siteman Cancer Center; Washington University St Louis, Missouri, 01/2013 - Present

Alternate approaches in the treatment of men with systemic Prostate cancer, Smilow Cancer Center, Yale University, New Haven, CT, 02/2013 - Present

## BIBLIOGRAPHY

#### Refereed Journal Publications/Original Papers

1. Kilari D, Mohile SG. Management of cancer in the older adult. Clin Geriatr Med. 2012 Feb;28(1):33-49.
2. Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M. An observational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer. J Mens Health. 2012 Sep 01;9(3):182-189. PMCID: PMC3886726
3. Kilari D, Venci N, Friedberg J, Bennett JM. Hemophagocytic lymphohistiocytosis masquerading as progressive chronic lymphocytic leukemia. Leuk Res Rep. 2013;2(1):4-6. PMCID: PMC3850386
4. Kilari D, Dale W, Mohile SG. How we treat early systemic prostate cancer in older men. J Geriatr Oncol. 2014 Oct 01;5(4):337-42.
5. Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer. 2014 Jul;85(1):88-93. PMCID: PMC4090351
6. Xia S, Kohli M, Du M, Dittmar RL, Lee A, Nandy D, Yuan T, Guo Y, Wang Y, Tschanen MR, Worthey E, Jacob H, See W, Kilari D, Wang X, Hovey RL, Huang CC, Wang L. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget. 2015 Jun 30;6(18):16411-21. PMCID: PMC4599278
7. Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget. 2017 Jan 10;8(2):3724-3745. PMCID: PMC5356914
8. Thompson JR, Zhu J, Kilari D, Wang L. Applications of Extracellular RNAs in Oncology. Mol Diagn Ther. 2017 Feb;21(1):1-11.
9. Flynn T, Guancial EA, Kilari M, Kilari D. Case Report: Spironolactone Withdrawal Associated With a Dramatic Response in a Patient With Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Feb;15(1):e95-e97.
10. Kilari D, Guancial E, Kim ES. Role of copper transporters in platinum resistance. World J Clin Oncol. 2016 Feb 10;7(1):106-13. PMCID: PMC4734932

11. Abbott DW, Kilari D, Seneboutrath K, Iczkowski KA. Squamous cell carcinoma of the prostate with concomitant adenocarcinoma in the absence of prior androgen deprivation therapy Case Reports in Clinical Pathology. 2016 June 01;3(2):60-63
12. Kilari D, Soto-Perez-de-Celis E, Mohile SG, Alibhai SM, Presley CJ, Wildes TM, Klepin HD, Demark-Wahnefried W, Jatoi A, Harrison R, Won E, Mustian KM. Designing exercise clinical trials for older adults with cancer: Recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting. *J Geriatr Oncol.* 2016 Jul;7(4):293-304. PMCID: PMC4969104
13. Guancial EA, Kilari D, Xiao GQ, Abu-Farsakh SH, Baran A, Messing EM, Kim ES. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. *PLoS One.* 2016;11(5):e0155503. PMCID: PMC4871463
14. Presley CJ, Dotan E, Soto-Perez-de-Celis E, Jatoi A, Mohile SG, Won E, Alibhai S, Kilari D, Harrison R, Klepin HD, Wildes TM, Mustian K, Demark-Wahnefried W. Gaps in nutritional research among older adults with cancer. *J Geriatr Oncol.* 2016 Jul;7(4):281-92. PMCID: PMC4969118
15. Kilari D, Iczkowski KA, Pandya C, Robin AJ, Messing EM, Guancial E, Kim ES. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients. *Anticancer Res.* 2016 Feb;36(2):495-501.
16. Raychaudhuri R, Riese MJ, Bylow K, Burfeind J, Mackinnon AC, Tolat PP, Iczkowski KA, Kilari D. Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm. *Clin Genitourin Cancer.* 2017 Oct;15(5):e897-e901.
17. Du M, Giridhar KV, Tian Y, Tschannen MR, Zhu J, Huang CC, Kilari D, Kohli M, Wang L. Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. *Oncotarget.* 2017 Sep 08;8(38):63703-63714. PMCID: PMC5609954
18. Kapke J, Shaheen Z, Kilari D, Knudson P, Wong S. Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. *Case Rep Oncol.* 2017;10(3):897-909. PMCID: PMC5731100
19. Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. *Prostate Cancer Prostatic Dis.* 2018 Sep;21(3):411-418. PMCID: PMC6126974

## **Abstracts**

1. Kilari D, Carmel R, Dosik, H, Bellevue. Priapism: the first manifestation of Sickle cell trait. Poster presentation at the Society of General Internal Medicine (SGIM) annual meeting, 2008 May 01;Pittsburgh, PA.
2. Kilari D, Chakraborty S, Politsmakher A, Carmel R, Dosik, Hassan, S. Use of Advanced Care Directives by Ambulatory Chemotherapy Patients with various malignancies. Poster presentation at the New York Methodist Hospital (NYMH) Annual Research Retreat, 2009, New York, NY.
3. Kilari D, Carmel R, Gerecitano J. Methotrexate-related Lymphoproliferative disorders. Poster Presentation at the New York Chapter of American College of Physicians (NYACP) Annual Meeting 2009; New York, NY
4. Haque M, Kilari D, Bellevue R, Dosik H. Chronic Myeloid leukemia (CML) in a patient with sickle cell disease, Poster Presentation at the New York Methodist Hospital Resident Research day: Annual meeting, 2010 New York, NY.
5. Ninan N, Wentowski C, Sudore P, Abdelwahed A, Kilari D, Bellevue R, George L, MD. The Association Between Lipid Levels and Pulmonary Hypertension in Patients With Sickle Cell Disease. Poster presented at the American College of Chest Physicians (ACCP), Annual Meeting, 2010, Vancouver, British Columbia.
6. Kilari D, Pandya C, Fung C, Sahasrabudhe D, Brasacchio RA, Messing EM, Sievert L, Gupta SM; Characteristics and Outcomes of the elderly patients treated with peripheral androgen blockade. Poster presented at the Genitourinary American Society of Clinical Oncology (GU- ASCO), Annual Meeting, 2013, Orlando, Florida. *J Clinical Oncology* 31, 2013 (suppl 6; abstract 226)
7. Kilari D, Yao J, Scosyrev E, Evans EE, Sahasrabudhe DM; C35 a new prognostic tool and potential therapeutic target in patients with Prostate cancer. Poster presented at the Genitourinary American Society of Clinical Oncology (GU- ASCO), Annual Meeting, 2013, Orlando, Florida. *J Clinical Oncology* 31, 2013 (suppl 6; abstract 212)
8. Kilari D, Pandya C, Fung C, Sahasrabudhe D, Brasacchio RA, Messing EM, Sievert L, Gupta SM; The role of

- Comprehensive Geriatric Assessment (CGA) in identifying Elderly patients with Systemic Prostate Cancer (PCa) for Peripheral Androgen Blockade (PAB). Poster presented at the American Geriatric Society, annual meeting 2013. Grapevine, Texas.
- 9. Kilari D, Tang X, Chow C, Fujimoto J, Kalhor N, Swisher S, Wistuba I, Stewart DJ, Siddik ZH, Kim ES, Copper transporter expression (CTR1) and tissue platinum concentration in Non-small cell lung cancer. Poster Presented at the American Society of Clinical Oncology (ASCO), Annual Meeting, 2013, Chicago, IL. *J Clinical Oncology* 31, 2013 (suppl; abstract 2601)
  - 10. Guancial E, Kilari D, Messing EM, Kim ES; Platinum concentration in bladder tissue treated with neoadjuvant chemotherapy and pathologic response. Poster Presented at the Genitourinary American Society of Clinical Oncology (GU- ASCO), Annual Meeting, 2015, San Francisco, CA. *J Clinical Oncology* 33, 2015 (suppl 7; abstract 341)
  - 11. Kilari D, Iczkowski KA, Robin A, Pandya C, Messing EM, Guancial EA, Kim ES. Association between Copper Transporter Receptor 1(CTR1) Expression and Pathologic Outcomes in Platinum (Pt)-treated Bladder Cancer (BC) patients. Presented at the European Cancer Congress, annual meeting 2015, Vienna Austria.
  - 12. Kilari D, Guancial E, Sahasrabudhe D, Bylow D, Burfeind J, Musto K, Feng C, Messing E, Mohile SG, Fung C.A Phase II Study of Enzalutamide (Enz) with Dutasteride (Dut) or Finasteride (Fin) in Men ? 65 Years with Hormone-naive Systemic Prostate Cancer (HNSPCa). Poster at GU ASCO, Feb 2017, Orlando, FL.
  - 13. S Ramalingam, A Szabo, D Kilari, C Bhosekar, J Karpinski, SWong; Mannitol Enhances Cumulative Cisplatin Dose by Protecting against Cisplatin-Induced Nephrotoxicity Poster at ASCO 2017.
  - 14. J. F. Borkenhagen, D. Eastwood, D. Kilari, W. A. See, J. D. Van Wickle, C. A. Lawton, W. A. Hall Prognostic Value of Clinical Stage T2 Substages in Prostate Cancer: A National Cancer Database Review. Poster at ASTRO 2017.
  - 15. W. A. Hall, D Eastwood, D Kilari, J Wickle, R Raychaudhuri, J Borkenhagen, W See, C Lawton Androgen Deprivation Therapy (ADT) and Radiation Therapy (RT) Alone As Compared with Trimodality Therapy With ADT, RT, and Surgery In Men With High Risk, Non-Metastatic Adenocarcinoma Of The Prostate: Oral presentation at ASTRO 2017.
  - 16. D Kilari, E Guancial2, D Sahasrabudhe, S Mohile, C Fung. Phase II Study of Enzalutamide (Enz) with Dutasteride (Dut) or Finasteride (Fin) in Men ? 65 Years with Hormone-naive Systemic Prostate Cancer (HNSPCa): Updated analysis: Poster at ESMO Madrid, Spain 2017.
  - 17. A. Singavi, S. Menon, D. Kilari, A. Alqwasmi, P.S. Ritch, J.P. Thomas, A.L. Martin, C. Oxencis, S. Ali, B. George. Predictive biomarkers for Hyper-progression (HP) in response to Immune Checkpoint Inhibitors (ICI) – Analysis of Somatic Alterations (SAs) Poster at ESMO Madrid, Spain 2017.
  - 18. D Kilari, P Hari, M Qayed, R Fraser, O Davila, S Kumar, TM Mark, Y Nieto, A D'Souza; Tandem high dose chemotherapy and autologous hematopoietic stem cell transplantation (SCT) is superior to single SCT for relapsed/refractory germ cell tumors (GCT). Poster at GU ASCO Feb 2018, San Francisco, California.
  - 19. D. Petrylak, D. Smith, T.W. Flaig, J. Zhang, S.S. Sridhar, J. Ruether, E. Plimack, J. Merchan, D. Quinn, D. Kilari, S. Srinivas, J. Baranda, J. Lang, M. Milowsky, M. Galsky, A. Spira, E. Gartner, C. Wu, A. Melhem-Bertrandt, J.E. RosenbergEnfortumab Vedotin in Patients with Metastatic Urothelial Carcinoma with Prior Checkpoint Inhibitor Failure: A Prospective Cohort of an Ongoing Phase 1 Study. Poster at GU ASCO Feb 2018, San Francisco, California.
  - 20. R Raychaudhuri, K Bylow, W Lea, T Zellmer, K Musto, J Burfeind, M Riese, D Kilari Liver-Directed Therapy (LDT) for Metastatic Renal Cell Carcinoma (mRCC): Single center experience. Poster at GU ASCO Feb 2018, San Francisco, California.
  - 21. K. Bylow, D Kilari, M Riese, J Burfeind, M Stolley, R Prost, K Musto, R Neilson, A Szabo, J Thomas, AV. Ng, Effect of -hydroxy- -methyl butyrate (HMB) on muscle strength in older men with prostate cancer (PCA) started on androgen deprivation therapy (ADT): Preliminary results of an open-label, randomized trial. Poster, GU ASCO Feb 2018 San Francisco, California.
  - 22. Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kamble RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Wirk B, Yared JA, Nieto Y, Hari P. Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. *Biol Blood Marrow Transplant*. 2019 Jun;25(6):1099-1106. PMCID: PMC6559839
  - 23. Robbins JR, Kilari D, Johnston F. Palliative care education for oncologists: how are we doing? *Ann Palliat Med*

- Med. 2019 Sep;8(4):364-371.
24. Borkenhagen JF, Eastwood D, Kilari D, See WA, Van Winkle JD, Lawton CA, Hall WA. Digital Rectal Examination Remains a Key Prognostic Tool for Prostate Cancer: A National Cancer Database Review. *J Natl Compr Canc Netw.* 2019 Jul 01;17(7):829-837.
25. Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M. An observational study of plasma vascular endothelial growth factors (vegf) a and d expression in non-localized prostate cancer *Journal of Men's Health.* September 2012;9(3):182-189.
26. Udhane V, Maranto C, Hoang DT, Gu L, Erickson A, Devi S, Talati PG, Banerjee A, Iczkowski KA, Jacobsohn K, See WA, Mirtti T, Kilari D, Nevalainen MT. Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. *Mol Cancer Ther.* 2020 Jan;19(1):231-246. PMCID: PMC6946850
27. Lemke E, Sahasrabudhe D, Guanciale E, Bylow K, Johnson S, Messing E, Kilari D. The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020? *Clin Genitourin Cancer.* 2020 Aug;18(4):e478-e483.
28. Du M, Tian Y, Tan W, Wang L, Wang L, Kilari D, Huang CC, Wang L, Kohli M. Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer. *Prostate Cancer Prostatic Dis.* 2020 Dec;23(4):705-713. PMCID: PMC7501185
29. George G, Schmidt L, Tolat P, Riese M, Kilari D. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma. *J Immunother Cancer.* 2020 Feb;8(1). PMCID: PMC7057424
30. Kmaka JA, Agarwal N, He Y, Heilmann AM, Miller VA, Ross JS, Pal SK, Ali SM, Kilari D. Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation. *Case Rep Oncol.* 2020;13(1):456-461. PMCID: PMC7204854
31. Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, Patel V, Oh WK, Chinnaiyan A, Pritchard CC, Armstrong AJ, Montgomery RB, Alva A. CDK12-mutated prostate cancer: Clinical outcomes with standard therapies and immune checkpoint blockade *JCO Precision Oncology.* 2019;3:382-392.
32. Pierro M, Raychaudhuri R, Lea WB, Rilling W, Davis N, Bylow K, Kilari D. Outcomes With Liver-Directed Therapy for Genitourinary Malignancies: Single-Institution Experience. *Clin Genitourin Cancer.* 2021 Feb;19(1):87-91.
33. Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, Patel V, Oh WK, Chinnaiyan A, Pritchard CC, Armstrong AJ, Montgomery RB, Alva A. CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. *JCO Precis Oncol.* 2020;4:382-392. PMCID: PMC7363399
34. Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhooh H, Bilen MA. Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort *Frontiers in Oncology.* 22 October 2020;10.
35. Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhooh H, Bilen MA. Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. *Front Oncol.* 2020;10:581189. PMCID: PMC7642690
36. Hall WA, Bedi M, Kilari D, Bylow KA, Burfeind J, Johnstone C, Siker M, Currey A, See WA, Nelson A, Johnson S, Straza M, Lawton CAF. Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial. *Pract Radiat Oncol.* 2021;11(6):527-533. PMCID: PMC8638529
37. Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham LS, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen SR, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Heath E, Marshall CH, Tagawa ST, Halabi S, Schweizer MT, Armstrong A, Dorff T, Alva A, McKay R. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. *Prostate Cancer Prostatic Dis.* 2022 Sep;25(3):388-396. PMCID: PMC9385488
38. Beinhoff P, Sabharwal L, Udhane V, Maranto C, LaViolette PS, Jacobsohn KM, Tsai S, Iczkowski KA, Wang L, Hall WA, Dehm SM, Kilari D, Nevalainen MT. Second-Generation Jak2 Inhibitors for

- Advanced Prostate Cancer: Are We Ready for Clinical Development? *Cancers* (Basel). 2021 Oct 17;13(20). PMCID: PMC8533841
39. Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekho H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. *Cancer*. 2022 Mar 15;128(6):1194-1205.
40. Huang J, Du M, Soupir A, Wang L, Tan W, Kalari KR, Kilari D, Park J, Huang CC, Kohli M, Wang L. Plasma Copy Number Alteration-Based Prognostic and Predictive Multi-Gene Risk Score in Metastatic Castration-Resistant Prostate Cancer. *Cancers* (Basel). 2022 Sep 28;14(19). PMCID: PMC9562906
41. Mehra N, Fizazi K, de Bono JS, Barthélémy P, Dorff T, Stirling A, Machiels JP, Bimbatti D, Kilari D, Dumez H, Buttiglieri C, van Oort IM, Castro E, Chen HC, Di Santo N, DeAnnuntis L, Healy CG, Scagliotti GV. Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. *Oncologist*. 2022 Oct 01;27(10):e783-e795. PMCID: PMC9526483
42. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B, ARASENS Trial Investigators. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. *N Engl J Med*. 2022 Mar 24;386(12):1132-1142. PMCID: PMC9844551
43. Shayeb AM, McManus HD, Urman D, Jani C, Zhang T, Dizman N, Meza L, Sivakumar A, Gan CL, Barata P, Bilen MA, Gao X, Heng D, Pal S, Narra R, Kilari D, Kaymakcalan MD, McGregor B, Choueiri TK, McKay RR. Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2023 Feb;21(1):55-62.
44. Stevens-Haas C, Maniar V, Dietrich P, Langenstroer P, Joyce L, White S, Kilari D, Hong J, Johnson S. Management of Acute Liver Dysfunction Due to Budd-Chiari Syndrome in the Setting of Tumor Thrombus and Advanced Renal Cell Carcinoma. *Urology*. 2023 Mar;173:32-33.
45. Gallan AJ, Bhasin-Chhabra B, Kilari D, Johnson S, D'Souza A. Bystander LECT2 amyloidosis in tumor nephrectomy. *CEN Case Rep*. 2023 Feb;12(1):104-109. PMCID: PMC9892383
46. Pierro MJ, Kilari D. The Confusion Surrounding Androgen Deprivation Therapy and Cognitive Dysfunction. *Eur Urol Focus*. 2023 May;9(3):409-410.
47. Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekho H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y. Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. *J Immunother Cancer*. 2023 Feb;11(2). PMCID: PMC9950974
48. Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B. Comprehensive genomic profiling: Does timing matter? *Frontiers in Oncology*. 2023;13.
49. Hakimi K, Saidian A, Panian J, Barata P, Berg S, Chang SL, Saliby RM, Dzimitrowicz H, Emamekho H, Gross E, Kilari D, Lam E, Nguyen M, Meagher M, Wang L, Rauterkus GP, D'Andrea V, Yim K, Psutka S, Thapa B, Weise N, Zhang T, McKay RR, Derweesh IH. Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis. *Clin Genitourin Cancer*. 2023 Dec;21(6):694-702.
50. Panian J, Saidian A, Hakimi K, Ajmera A, Anderson WJ, Barata P, Berg S, Signoretti S, Lee Chang S, D'Andrea V, George D, Dzimitrowicz H, El Zarif T, Emamekho H, Gross E, Kilari D, Lam E, Lashgari I, Psutka S, Rauterkus GP, Shabaik A, Thapa B, Wang L, Weise N, Yim K, Zhang T, Derweesh I, McKay RR. Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy. *Oncologist*. 2023 Jun 27.
51. Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B. Comprehensive genomic profiling: Does timing matter? *Front Oncol*. 2023;13:1025367. PMCID: PMC9971445
52. Hwang C, Henderson NC, Chu SC, Holland B, Cackowski FC, Pilling A, Jang A, Rothstein S, Labriola M, Park JJ, Ghose A, Bilen MA, Mustafa S, Kilari D, Pierro MJ, Thapa B, Tripathi A, Garje R, Ravindra A, Koshkin VS, Hernandez E, Schweizer MT, Armstrong AJ, McKay RR, Dorff TB, Alva AS, Barata

- PC. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer. *JAMA Netw Open*. 2023 Sep 05;6(9):e2334208. PMCID: PMC10507489
53. Dorff T, Zengin Z, Henderson N, Ali A, Nguyen C, Hwang C, Barata PC, Bilen M, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A. Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration. *Res Sq*. 2023 Aug 10. PMCID: PMC10441451
54. Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalanen MT, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L. 5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapy. *medRxiv*. 2023 Oct 16. PMCID: PMC10615016
55. Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggner SE, Morris MJ, EORTC-55994 Study Group. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). *J Clin Oncol*. 2024 Jan 23;JCO2301157.